Free Trial

AnaptysBio (ANAB) Financials

AnaptysBio logo
$20.70 +0.09 (+0.44%)
Closing price 04:00 PM Eastern
Extended Trading
$19.94 -0.76 (-3.67%)
As of 07:17 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Annual Income Statements for AnaptysBio

Annual Income Statements for AnaptysBio

This table shows AnaptysBio's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Net Income / (Loss) Attributable to Common Shareholders
-129 -164 -145
Consolidated Net Income / (Loss)
-129 -164 -145
Net Income / (Loss) Continuing Operations
-129 -164 -145
Total Pre-Tax Income
-129 -164 -145
Total Operating Income
-115 -164 -115
Total Gross Profit
10 17 91
Total Revenue
10 17 91
Operating Revenue
10 17 91
Total Cost of Revenue
0.00 0.00 0.00
Total Operating Expenses
125 182 206
Selling, General & Admin Expense
37 42 42
Research & Development Expense
89 140 164
Total Other Income / (Expense), net
-14 0.79 -30
Interest Expense
21 18 50
Interest & Investment Income
7.55 19 20
Other Income / (Expense), net
0.01 -0.00 0.01
Income Tax Expense
0.02 -0.00 0.00
Basic Earnings per Share
($4.57) ($6.08) ($5.12)
Weighted Average Basic Shares Outstanding
28.17M 26.92M 28.38M
Diluted Earnings per Share
($4.57) ($6.08) ($5.12)
Weighted Average Diluted Shares Outstanding
28.17M 26.92M 28.38M
Weighted Average Basic & Diluted Shares Outstanding
27.93M 26.76M 30.67M

Quarterly Income Statements for AnaptysBio

This table shows AnaptysBio's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Income / (Loss) Attributable to Common Shareholders
-34 -26 -44 -40 -37 -42 -44 -47 -33 -22
Consolidated Net Income / (Loss)
-34 -26 -44 -40 -37 -42 -44 -47 -33 -22
Net Income / (Loss) Continuing Operations
-34 -26 -44 -40 -37 -42 -44 -47 -33 -22
Total Pre-Tax Income
-34 -26 -44 -40 -37 -42 -44 -47 -33 -22
Total Operating Income
-30 -26 -44 -40 -38 -42 -42 -40 -23 -9.67
Total Gross Profit
1.29 6.81 1.37 3.46 3.32 9.01 7.18 11 30 43
Total Revenue
1.29 6.81 1.37 3.46 3.32 9.01 7.18 11 30 43
Operating Revenue
1.29 6.81 1.37 3.46 3.32 9.01 7.18 11 30 43
Total Operating Expenses
31 33 46 44 41 51 49 51 53 53
Selling, General & Admin Expense
8.86 9.41 11 11 10 10 12 9.30 11 10
Research & Development Expense
22 23 35 33 31 41 37 42 42 43
Total Other Income / (Expense), net
-3.87 -0.42 0.15 0.30 0.42 -0.08 -1.74 -6.33 -10 -12
Interest Expense
6.14 4.25 4.34 4.36 4.43 4.96 6.32 11 15 17
Interest & Investment Income
2.26 3.84 4.49 4.65 4.85 4.88 4.58 4.62 5.32 5.26
Other Income / (Expense), net
0.00 -0.00 -0.00 0.00 0.00 -0.00 -0.00 0.00 -0.01 0.02
Basic Earnings per Share
($1.18) ($0.93) ($1.58) ($1.50) ($1.41) ($1.59) ($1.64) ($1.71) ($1.14) ($0.63)
Weighted Average Basic Shares Outstanding
28.29M 28.17M 27.95M 26.63M 26.55M 26.92M 26.80M 27.36M 28.89M 28.38M
Diluted Earnings per Share
($1.18) ($0.93) ($1.58) ($1.50) ($1.41) ($1.59) ($1.64) ($1.71) ($1.14) ($0.63)
Weighted Average Diluted Shares Outstanding
28.29M 28.17M 27.95M 26.63M 26.55M 26.92M 26.80M 27.36M 28.89M 28.38M
Weighted Average Basic & Diluted Shares Outstanding
28.43M 27.93M 26.49M 26.55M 26.58M 26.76M 27.32M 27.45M 30.43M 30.67M

Annual Cash Flow Statements for AnaptysBio

This table details how cash moves in and out of AnaptysBio's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Net Change in Cash & Equivalents
-424 -35 87
Net Cash From Operating Activities
-74 -121 -135
Net Cash From Continuing Operating Activities
-74 -121 -135
Net Income / (Loss) Continuing Operations
-129 -164 -145
Consolidated Net Income / (Loss)
-129 -164 -145
Depreciation Expense
0.68 0.65 0.61
Amortization Expense
1.66 1.72 1.79
Non-Cash Adjustments To Reconcile Net Income
45 35 40
Changes in Operating Assets and Liabilities, net
7.38 5.11 -32
Net Cash From Investing Activities
-395 145 95
Net Cash From Continuing Investing Activities
-395 145 95
Purchase of Property, Plant & Equipment
-0.36 -0.81 -0.36
Purchase of Investments
-803 -304 -380
Sale and/or Maturity of Investments
408 449 476
Net Cash From Financing Activities
44 -59 127
Net Cash From Continuing Financing Activities
44 -59 127
Repurchase of Common Equity
0.00 -50 -0.95
Issuance of Common Equity
12 2.47 6.47
Other Financing Activities, net
32 -12 122
Cash Interest Paid
0.00 0.00 42

Quarterly Cash Flow Statements for AnaptysBio

This table details how cash moves in and out of AnaptysBio's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Change in Cash & Equivalents
-13 13 23 -59 -8.91 9.67 18 18 120 -69
Net Cash From Operating Activities
-18 -11 -25 -25 -36 -34 -37 -21 -10 -67
Net Cash From Continuing Operating Activities
-18 -11 -25 -25 -36 -34 -37 -21 -10 -67
Net Income / (Loss) Continuing Operations
-34 -26 -44 -40 -37 -42 -44 -47 -33 -22
Consolidated Net Income / (Loss)
-34 -26 -44 -40 -37 -42 -44 -47 -33 -22
Depreciation Expense
0.17 0.18 0.17 0.16 0.16 0.17 0.16 0.15 0.14 0.15
Amortization Expense
-0.37 1.21 0.43 0.42 0.43 0.44 0.44 0.44 0.45 0.46
Non-Cash Adjustments To Reconcile Net Income
13 8.19 11 8.94 9.16 6.33 13 14 18 -5.28
Changes in Operating Assets and Liabilities, net
2.96 6.15 8.19 4.91 -8.92 0.93 -7.16 11 4.32 -40
Net Cash From Investing Activities
-32 21 85 -20 31 49 69 -2.44 59 -29
Net Cash From Continuing Investing Activities
-32 21 85 -20 31 49 69 -2.44 59 -29
Purchase of Property, Plant & Equipment
-0.05 -0.18 -0.18 -0.19 -0.16 -0.28 -0.03 -0.03 -0.04 -0.26
Purchase of Investments
-180 -128 -49 -119 -70 -66 -59 -149 -51 -121
Sale and/or Maturity of Investments
148 149 134 99 101 116 128 147 110 92
Net Cash From Financing Activities
37 1.95 -38 -13 -3.07 -5.16 -14 42 71 28
Net Cash From Continuing Financing Activities
37 1.95 -38 -13 -3.07 -5.16 -14 42 71 28
Repurchase of Common Equity
- - -38 -12 - - 0.00 - -0.37 -0.58
Issuance of Common Equity
2.70 3.42 1.27 0.78 0.16 0.26 0.81 0.98 4.13 0.56
Other Financing Activities, net
35 -1.76 -1.27 -1.80 -3.23 -5.47 -14 41 68 27

Annual Balance Sheets for AnaptysBio

This table presents AnaptysBio's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Total Assets
610 452 484
Total Current Assets
447 407 432
Cash & Equivalents
71 36 123
Short-Term Investments
370 355 262
Accounts Receivable
1.42 6.85 41
Prepaid Expenses
4.55 9.08 5.74
Plant, Property, & Equipment, net
2.09 2.10 1.85
Total Noncurrent Assets
161 43 50
Long-Term Investments
143 27 35
Other Noncurrent Operating Assets
18 16 15
Total Liabilities & Shareholders' Equity
610 452 484
Total Liabilities
348 364 413
Total Current Liabilities
26 37 45
Accounts Payable
2.78 4.70 4.00
Accrued Expenses
22 31 40
Other Current Liabilities
1.64 1.78 1.93
Total Noncurrent Liabilities
322 327 368
Other Noncurrent Operating Liabilities
322 327 368
Total Equity & Noncontrolling Interests
262 88 71
Total Preferred & Common Equity
262 88 71
Preferred Stock
0.00 0.00 0.00
Total Common Equity
262 88 71
Common Stock
718 703 830
Retained Earnings
-450 -614 -759
Accumulated Other Comprehensive Income / (Loss)
-5.25 -0.80 0.31

Quarterly Balance Sheets for AnaptysBio

This table presents AnaptysBio's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024
Total Assets
619 552 517 487 406 427 493
Total Current Assets
450 437 439 428 372 367 449
Cash & Equivalents
59 95 35 26 54 72 192
Short-Term Investments
384 337 394 387 301 279 239
Accounts Receivable
1.18 1.52 3.18 3.27 7.09 9.01 12
Prepaid Expenses
6.30 4.48 5.87 12 11 7.54 6.37
Plant, Property, & Equipment, net
1.97 1.98 2.02 2.25 1.95 1.83 1.73
Total Noncurrent Assets
166 113 77 57 31 58 43
Long-Term Investments
148 95 59 40 15 43 28
Other Noncurrent Operating Assets
19 18 17 17 16 16 15
Total Liabilities & Shareholders' Equity
619 552 517 487 406 427 493
Total Liabilities
341 361 369 367 358 417 409
Total Current Liabilities
21 36 42 39 32 40 44
Accounts Payable
3.01 3.17 4.76 6.52 4.58 4.89 3.59
Accrued Expenses
16 31 35 31 26 34 38
Other Current Liabilities
1.60 1.67 1.71 1.74 1.81 1.85 1.89
Total Noncurrent Liabilities
320 325 327 328 326 377 365
Other Noncurrent Operating Liabilities
320 325 327 328 326 377 365
Total Equity & Noncontrolling Interests
278 191 148 120 48 9.88 84
Total Preferred & Common Equity
278 191 148 120 48 9.88 84
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
278 191 148 120 48 9.88 84
Common Stock
708 689 687 695 706 715 821
Retained Earnings
-424 -495 -535 -572 -658 -705 -738
Accumulated Other Comprehensive Income / (Loss)
-6.01 -3.27 -3.61 -2.35 -0.62 -0.42 0.76

Annual Metrics and Ratios for AnaptysBio

This table displays calculated financial ratios and metrics derived from AnaptysBio's official financial filings.

Metric 2022 2023 2024
Growth Metrics
- - -
Revenue Growth
-83.72% 66.78% 432.03%
EBITDA Growth
-106.28% -43.64% 30.55%
EBIT Growth
-102.80% -42.79% 30.09%
NOPAT Growth
-102.69% -42.77% 30.08%
Net Income Growth
-122.72% -27.11% 11.24%
EPS Growth
-116.59% -33.04% 15.79%
Operating Cash Flow Growth
-60.26% -64.15% -12.03%
Free Cash Flow Firm Growth
-108.46% -520.40% 43.80%
Invested Capital Growth
-24.47% -2.41% -6.11%
Revenue Q/Q Growth
129.11% 14.69% 59.66%
EBITDA Q/Q Growth
5.20% -11.68% 22.40%
EBIT Q/Q Growth
4.30% -10.90% 22.04%
NOPAT Q/Q Growth
4.31% -10.90% 22.02%
Net Income Q/Q Growth
4.54% -10.69% 12.33%
EPS Q/Q Growth
5.38% -12.18% 15.79%
Operating Cash Flow Q/Q Growth
16.57% -24.36% -31.38%
Free Cash Flow Firm Q/Q Growth
-107.76% -28.14% 3.33%
Invested Capital Q/Q Growth
-2.95% 0.91% 6.34%
Profitability Metrics
- - -
Gross Margin
100.00% 100.00% 100.00%
EBITDA Margin
-1,096.60% -944.44% -123.29%
Operating Margin
-1,119.41% -958.27% -125.93%
EBIT Margin
-1,119.30% -958.29% -125.91%
Profit (Net Income) Margin
-1,251.33% -953.66% -159.11%
Tax Burden Percent
100.02% 100.00% 100.00%
Interest Burden Percent
111.78% 99.52% 126.36%
Effective Tax Rate
0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00%
Return on Equity (ROE)
-41.62% -93.44% -182.71%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
-18.37% -30.94% -24.55%
Return on Assets (ROA)
-20.54% -30.79% -31.02%
Return on Common Equity (ROCE)
-41.62% -93.44% -182.71%
Return on Equity Simple (ROE_SIMPLE)
-49.11% -185.71% -204.93%
Net Operating Profit after Tax (NOPAT)
-81 -115 -80
NOPAT Margin
-783.59% -670.79% -88.15%
Net Nonoperating Expense Percent (NNEP)
-8.02% -9.69% -15.44%
Return On Investment Capital (ROIC_SIMPLE)
-30.75% -130.63% -113.54%
Cost of Revenue to Revenue
0.00% 0.00% 0.00%
SG&A Expenses to Revenue
356.21% 244.48% 46.44%
R&D to Revenue
863.21% 813.79% 179.49%
Operating Expenses to Revenue
1,219.41% 1,058.27% 225.93%
Earnings before Interest and Taxes (EBIT)
-115 -164 -115
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-113 -162 -113
Valuation Ratios
- - -
Price to Book Value (P/BV)
3.36 6.46 5.68
Price to Tangible Book Value (P/TBV)
3.36 6.46 5.68
Price to Revenue (P/Rev)
85.65 33.18 4.41
Price to Earnings (P/E)
0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
28.86 8.82 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00
Leverage & Solvency
- - -
Debt to Equity
0.00 0.00 0.00
Long-Term Debt to Equity
0.00 0.00 0.00
Financial Leverage
-1.94 -2.86 -5.28
Leverage Ratio
2.03 3.03 5.89
Compound Leverage Factor
2.27 3.02 7.44
Debt to Total Capital
0.00% 0.00% 0.00%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00%
Common Equity to Total Capital
100.00% 100.00% 100.00%
Debt to EBITDA
0.00 0.00 0.00
Net Debt to EBITDA
0.00 0.00 0.00
Long-Term Debt to EBITDA
0.00 0.00 0.00
Debt to NOPAT
0.00 0.00 0.00
Net Debt to NOPAT
0.00 0.00 0.00
Long-Term Debt to NOPAT
0.00 0.00 0.00
Altman Z-Score
0.71 -1.14 -1.25
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00%
Liquidity Ratios
- - -
Current Ratio
17.16 10.87 9.51
Quick Ratio
16.99 10.62 9.38
Cash Flow Metrics
- - -
Free Cash Flow to Firm (FCFF)
-17 -107 -60
Operating Cash Flow to CapEx
-20,556.70% -14,969.02% -37,803.63%
Free Cash Flow to Firm to Interest Expense
-0.82 -5.94 -1.20
Operating Cash Flow to Interest Expense
-3.49 -6.68 -2.70
Operating Cash Flow Less CapEx to Interest Expense
-3.50 -6.72 -2.71
Efficiency Ratios
- - -
Asset Turnover
0.02 0.03 0.20
Accounts Receivable Turnover
8.96 4.15 3.83
Inventory Turnover
0.00 0.00 0.00
Fixed Asset Turnover
4.71 8.20 46.25
Accounts Payable Turnover
0.00 0.00 0.00
Days Sales Outstanding (DSO)
40.72 87.97 95.20
Days Inventory Outstanding (DIO)
0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00
Cash Conversion Cycle (CCC)
40.72 87.97 95.20
Capital & Investment Metrics
- - -
Invested Capital
-322 -330 -350
Invested Capital Turnover
-0.04 -0.05 -0.27
Increase / (Decrease) in Invested Capital
-63 -7.75 -20
Enterprise Value (EV)
297 151 -18
Market Capitalization
881 569 403
Book Value per Share
$9.22 $3.32 $2.33
Tangible Book Value per Share
$9.22 $3.32 $2.33
Total Capital
262 88 71
Total Debt
0.00 0.00 0.00
Total Long-Term Debt
0.00 0.00 0.00
Net Debt
-584 -418 -421
Capital Expenditures (CapEx)
0.36 0.81 0.36
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-20 -22 1.08
Debt-free Net Working Capital (DFNWC)
421 369 386
Net Working Capital (NWC)
421 369 386
Net Nonoperating Expense (NNE)
48 49 65
Net Nonoperating Obligations (NNO)
-584 -418 -421
Total Depreciation and Amortization (D&A)
2.34 2.38 2.40
Debt-free, Cash-free Net Working Capital to Revenue
-195.30% -125.38% 1.18%
Debt-free Net Working Capital to Revenue
4,094.01% 2,153.02% 423.37%
Net Working Capital to Revenue
4,094.01% 2,153.02% 423.37%
Earnings Adjustments
- - -
Adjusted Basic Earnings per Share
($4.57) ($6.08) ($5.12)
Adjusted Weighted Average Basic Shares Outstanding
28.17M 26.92M 28.38M
Adjusted Diluted Earnings per Share
($4.57) ($6.08) ($5.12)
Adjusted Weighted Average Diluted Shares Outstanding
28.17M 26.92M 28.38M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
27.93M 26.76M 30.67M
Normalized Net Operating Profit after Tax (NOPAT)
-81 -115 -80
Normalized NOPAT Margin
-783.59% -670.79% -88.15%
Pre Tax Income Margin
-1,251.09% -953.68% -159.10%
Debt Service Ratios
- - -
EBIT to Interest Expense
-5.45 -9.09 -2.29
NOPAT to Interest Expense
-3.82 -6.36 -1.61
EBIT Less CapEx to Interest Expense
-5.47 -9.14 -2.30
NOPAT Less CapEx to Interest Expense
-3.84 -6.41 -1.61
Payout Ratios
- - -
Dividend Payout Ratio
0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% -30.56% -0.65%

Quarterly Metrics and Ratios for AnaptysBio

This table displays calculated financial ratios and metrics derived from AnaptysBio's official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Growth Metrics
- - - - - - - - - -
Revenue Growth
-93.81% 573.39% 41.65% 184.54% 156.61% 32.27% 422.49% 217.08% 804.67% 378.77%
EBITDA Growth
-392.13% 20.10% -41.29% -44.44% -24.51% -68.92% 5.05% -0.44% 40.32% 78.21%
EBIT Growth
-340.25% 16.62% -39.89% -44.42% -27.34% -62.21% 4.96% -0.45% 39.67% 77.10%
NOPAT Growth
-338.16% 16.64% -39.85% -44.40% -27.33% -62.23% 4.95% -0.44% 39.69% 77.05%
Net Income Growth
-402.58% 18.82% -22.07% -22.40% -11.36% -59.81% 0.72% -17.10% 11.95% 48.39%
EPS Growth
-391.67% 21.85% -20.61% -30.43% -19.49% -70.97% -3.80% -14.00% 19.15% 60.38%
Operating Cash Flow Growth
-153.31% 57.77% -16.91% -5.23% -105.52% -221.47% -51.63% 16.08% 72.34% -94.10%
Free Cash Flow Firm Growth
2,250.46% -79.71% -84.12% -81.34% -102.24% -148.18% -211.44% -66.01% 488.34% 161.54%
Invested Capital Growth
-5,333.45% -24.47% -25.90% -27.05% -6.40% -2.41% 3.77% -12.72% -12.26% -6.11%
Revenue Q/Q Growth
6.33% 426.53% -79.82% 151.82% -4.10% 171.40% -20.28% 52.82% 173.60% 43.63%
EBITDA Q/Q Growth
-8.93% 17.57% -78.19% 9.72% 6.10% -11.83% -21.75% 4.50% 44.20% 59.18%
EBIT Q/Q Growth
-6.61% 12.33% -70.94% 9.60% 6.00% -11.68% -0.16% 4.46% 43.55% 57.61%
NOPAT Q/Q Growth
-6.60% 12.35% -70.95% 9.59% 6.01% -11.67% -0.16% 4.45% 43.56% 57.51%
Net Income Q/Q Growth
-2.91% 21.16% -67.55% 9.97% 6.37% -13.14% -4.09% -6.20% 29.59% 33.69%
EPS Q/Q Growth
-2.61% 21.19% -69.89% 5.06% 6.00% -12.77% -3.14% -4.27% 33.33% 44.74%
Operating Cash Flow Q/Q Growth
26.50% 39.79% -129.93% -3.42% -43.55% 5.83% -8.45% 42.76% 52.68% -560.77%
Free Cash Flow Firm Q/Q Growth
20.47% -84.24% -16.15% 17.20% -114.44% -239.51% -93.96% 135.74% 65.00% -46.20%
Invested Capital Q/Q Growth
-16.81% -2.95% -4.01% -1.58% 2.18% 0.91% 2.26% -18.99% 2.58% 6.34%
Profitability Metrics
- - - - - - - - - -
Gross Margin
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin
-2,306.88% -361.15% -3,188.65% -1,143.15% -1,119.32% -461.22% -579.44% -362.10% -73.84% -20.99%
Operating Margin
-2,291.80% -381.51% -3,231.51% -1,160.20% -1,137.19% -467.91% -587.84% -367.52% -75.81% -22.43%
EBIT Margin
-2,291.49% -381.57% -3,231.80% -1,160.12% -1,137.16% -467.93% -587.87% -367.52% -75.83% -22.38%
Profit (Net Income) Margin
-2,591.03% -387.97% -3,220.89% -1,151.59% -1,124.41% -468.75% -612.01% -425.30% -109.44% -50.53%
Tax Burden Percent
100.00% 100.09% 100.00% 100.00% 100.00% 99.99% 100.00% 100.02% 100.00% 99.97%
Interest Burden Percent
113.07% 101.59% 99.66% 99.27% 98.88% 100.19% 104.11% 115.70% 144.32% 225.83%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
-40.79% -41.62% -52.40% -63.62% -74.28% -93.44% -136.73% -214.89% -161.81% -182.71%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
-19.73% -6.26% -58.71% -26.77% -30.77% -15.11% -28.19% -23.72% -8.84% -4.36%
Return on Assets (ROA)
-22.31% -6.37% -58.51% -26.58% -30.42% -15.13% -29.35% -27.44% -12.76% -9.85%
Return on Common Equity (ROCE)
-40.79% -41.62% -52.40% -63.62% -74.28% -93.44% -136.73% -214.89% -161.81% -182.71%
Return on Equity Simple (ROE_SIMPLE)
-48.57% 0.00% -71.55% -97.01% -122.79% 0.00% -341.79% -1,721.99% -196.35% 0.00%
Net Operating Profit after Tax (NOPAT)
-21 -18 -31 -28 -26 -29 -30 -28 -16 -6.77
NOPAT Margin
-1,604.26% -267.05% -2,262.06% -812.14% -796.03% -327.53% -411.49% -257.27% -53.07% -15.70%
Net Nonoperating Expense Percent (NNEP)
-2.60% -1.37% -2.35% -2.21% -2.09% -2.54% -3.21% -4.18% -3.71% -3.58%
Return On Investment Capital (ROIC_SIMPLE)
- -6.94% - - - -33.48% - - - -9.55%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
685.38% 138.18% 787.34% 308.67% 306.57% 114.11% 171.86% 84.72% 35.19% 23.64%
R&D to Revenue
1,706.42% 343.33% 2,544.18% 951.53% 930.62% 453.79% 515.98% 382.80% 140.63% 98.78%
Operating Expenses to Revenue
2,391.80% 481.51% 3,331.51% 1,260.20% 1,237.19% 567.91% 687.84% 467.52% 175.81% 122.43%
Earnings before Interest and Taxes (EBIT)
-30 -26 -44 -40 -38 -42 -42 -40 -23 -9.65
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-30 -25 -44 -40 -37 -42 -42 -40 -22 -9.05
Valuation Ratios
- - - - - - - - - -
Price to Book Value (P/BV)
2.59 3.36 3.18 3.63 3.96 6.46 12.61 69.30 10.90 5.68
Price to Tangible Book Value (P/TBV)
2.59 3.36 3.18 3.63 3.96 6.46 12.61 69.30 10.90 5.68
Price to Revenue (P/Rev)
160.44 85.65 56.85 41.65 31.87 33.18 26.25 22.47 16.08 4.41
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
28.93 28.86 7.64 3.87 1.57 8.82 10.13 9.55 8.07 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.58 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - -
Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage
-1.48 -1.94 -2.15 -2.34 -2.62 -2.86 -3.75 -5.57 -4.45 -5.28
Leverage Ratio
1.58 2.03 2.26 2.48 2.78 3.03 4.01 5.97 4.79 5.89
Compound Leverage Factor
1.78 2.06 2.25 2.46 2.75 3.04 4.17 6.90 6.91 13.30
Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
0.99 1.19 0.38 0.12 -0.13 -0.25 -0.54 -0.65 0.20 -0.53
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - -
Current Ratio
21.39 17.16 12.21 10.53 10.92 10.87 11.53 9.09 10.23 9.51
Quick Ratio
21.09 16.99 12.09 10.39 10.63 10.62 11.20 8.90 10.08 9.38
Cash Flow Metrics
- - - - - - - - - -
Free Cash Flow to Firm (FCFF)
286 45 38 44 -6.40 -22 -42 15 25 13
Operating Cash Flow to CapEx
-35,494.00% -6,105.71% -14,038.86% -13,373.16% -22,514.81% -12,267.50% -137,974.07% -64,612.12% -28,828.57% -25,350.57%
Free Cash Flow to Firm to Interest Expense
46.68 10.62 8.73 10.18 -1.45 -4.38 -6.68 1.38 1.61 0.77
Operating Cash Flow to Interest Expense
-2.89 -2.51 -5.67 -5.83 -8.23 -6.93 -5.90 -1.95 -0.65 -3.83
Operating Cash Flow Less CapEx to Interest Expense
-2.90 -2.55 -5.71 -5.87 -8.27 -6.98 -5.90 -1.95 -0.66 -3.85
Efficiency Ratios
- - - - - - - - - -
Asset Turnover
0.01 0.02 0.02 0.02 0.03 0.03 0.05 0.06 0.12 0.20
Accounts Receivable Turnover
4.63 8.96 8.75 6.14 6.73 4.15 5.33 5.00 7.39 3.83
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
2.05 4.71 5.16 6.34 7.08 8.20 11.67 15.81 28.72 46.25
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)
78.89 40.72 41.72 59.47 54.27 87.97 68.45 73.00 49.36 95.20
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
78.89 40.72 41.72 59.47 54.27 87.97 68.45 73.00 49.36 95.20
Capital & Investment Metrics
- - - - - - - - - -
Invested Capital
-313 -322 -335 -340 -333 -330 -322 -384 -374 -350
Invested Capital Turnover
-0.03 -0.04 -0.04 -0.04 -0.05 -0.05 -0.07 -0.08 -0.16 -0.27
Increase / (Decrease) in Invested Capital
-307 -63 -69 -72 -20 -7.75 13 -43 -41 -20
Enterprise Value (EV)
130 297 82 50 24 151 233 291 462 -18
Market Capitalization
720 881 608 539 477 569 603 685 920 403
Book Value per Share
$9.83 $9.22 $6.84 $5.60 $4.54 $3.32 $1.79 $0.36 $3.07 $2.33
Tangible Book Value per Share
$9.83 $9.22 $6.84 $5.60 $4.54 $3.32 $1.79 $0.36 $3.07 $2.33
Total Capital
278 262 191 148 120 88 48 9.88 84 71
Total Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt
-590 -584 -526 -489 -453 -418 -370 -393 -458 -421
Capital Expenditures (CapEx)
0.05 0.18 0.18 0.19 0.16 0.28 0.03 0.03 0.04 0.26
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-14 -20 -30 -33 -24 -22 -15 -24 -25 1.08
Debt-free Net Working Capital (DFNWC)
429 421 401 397 389 369 340 327 405 386
Net Working Capital (NWC)
429 421 401 397 389 369 340 327 405 386
Net Nonoperating Expense (NNE)
13 8.23 13 12 11 13 14 18 17 15
Net Nonoperating Obligations (NNO)
-590 -584 -526 -489 -453 -418 -370 -393 -458 -421
Total Depreciation and Amortization (D&A)
-0.20 1.39 0.59 0.59 0.59 0.60 0.61 0.60 0.60 0.60
Debt-free, Cash-free Net Working Capital to Revenue
-302.56% -195.30% -278.66% -251.89% -161.93% -125.38% -63.34% -78.34% -44.28% 1.18%
Debt-free Net Working Capital to Revenue
9,563.05% 4,094.01% 3,754.18% 3,068.45% 2,599.08% 2,153.02% 1,481.24% 1,072.85% 708.04% 423.37%
Net Working Capital to Revenue
9,563.05% 4,094.01% 3,754.18% 3,068.45% 2,599.08% 2,153.02% 1,481.24% 1,072.85% 708.04% 423.37%
Earnings Adjustments
- - - - - - - - - -
Adjusted Basic Earnings per Share
($1.18) ($0.93) ($1.58) ($1.50) ($1.41) ($1.59) ($1.64) ($1.71) ($1.14) ($0.63)
Adjusted Weighted Average Basic Shares Outstanding
28.29M 28.17M 27.95M 26.63M 26.55M 26.92M 26.80M 27.36M 28.89M 28.38M
Adjusted Diluted Earnings per Share
($1.18) ($0.93) ($1.58) ($1.50) ($1.41) ($1.59) ($1.64) ($1.71) ($1.14) ($0.63)
Adjusted Weighted Average Diluted Shares Outstanding
28.29M 28.17M 27.95M 26.63M 26.55M 26.92M 26.80M 27.36M 28.89M 28.38M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
28.43M 27.93M 26.49M 26.55M 26.58M 26.76M 27.32M 27.45M 30.43M 30.67M
Normalized Net Operating Profit after Tax (NOPAT)
-21 -18 -31 -28 -26 -29 -30 -28 -16 -6.77
Normalized NOPAT Margin
-1,604.26% -267.05% -2,262.06% -812.14% -796.03% -327.53% -411.49% -257.27% -53.07% -15.70%
Pre Tax Income Margin
-2,591.03% -387.62% -3,220.89% -1,151.59% -1,124.41% -468.80% -612.01% -425.22% -109.44% -50.54%
Debt Service Ratios
- - - - - - - - - -
EBIT to Interest Expense
-4.83 -6.11 -10.24 -9.21 -8.52 -8.50 -6.68 -3.68 -1.48 -0.55
NOPAT to Interest Expense
-3.38 -4.28 -7.17 -6.45 -5.96 -5.95 -4.68 -2.58 -1.03 -0.39
EBIT Less CapEx to Interest Expense
-4.84 -6.15 -10.28 -9.25 -8.55 -8.56 -6.69 -3.68 -1.48 -0.57
NOPAT Less CapEx to Interest Expense
-3.39 -4.32 -7.21 -6.49 -6.00 -6.01 -4.68 -2.58 -1.04 -0.40
Payout Ratios
- - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% -27.45% -34.72% -33.82% -30.56% -7.64% 0.00% -0.22% -0.65%

Frequently Asked Questions About AnaptysBio's Financials

When does AnaptysBio's financial year end?

According to the most recent income statement we have on file, AnaptysBio's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has AnaptysBio's net income changed over the last 2 years?

AnaptysBio's net income appears to be on an upward trend, with a most recent value of -$145.23 million in 2024, rising from -$128.72 million in 2022. The previous period was -$163.62 million in 2023.

What is AnaptysBio's operating income?
AnaptysBio's total operating income in 2024 was -$114.95 million, based on the following breakdown:
  • Total Gross Profit: $91.28 million
  • Total Operating Expenses: $206.23 million
How has AnaptysBio revenue changed over the last 2 years?

Over the last 2 years, AnaptysBio's total revenue changed from $10.29 million in 2022 to $91.28 million in 2024, a change of 787.3%.

How much debt does AnaptysBio have?

AnaptysBio's total liabilities were at $412.97 million at the end of 2024, a 13.4% increase from 2023, and a 18.6% increase since 2022.

How much cash does AnaptysBio have?

In the past 2 years, AnaptysBio's cash and equivalents has ranged from $35.97 million in 2023 to $123.08 million in 2024, and is currently $123.08 million as of their latest financial filing in 2024.

How has AnaptysBio's book value per share changed over the last 2 years?

Over the last 2 years, AnaptysBio's book value per share changed from 9.22 in 2022 to 2.33 in 2024, a change of -74.7%.



This page (NASDAQ:ANAB) was last updated on 4/25/2025 by MarketBeat.com Staff
From Our Partners